Payment overview · 2025
General Payments
$323.64
16 reported records · 11 companies
Healthcare provider profile · identity verified
Mohammad J Uddin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAY MINETTE, AL · NPI 1679654917
Verified facts
What the public records show
CMS Open Payments records show Mohammad J Uddin, MD received $323.64 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.41 | 17.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.21 | 15.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.40 | 12.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.09 | 8.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $26.49 | 8.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $21.79 | 6.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.99 | 6.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.84 | 6.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.19 | 6.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.37 | 6.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.86 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $323.64 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.40 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 175 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
175 | 37 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
219 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 216 |
| Amlodipine Besylate | Amlodipine Besylate | 598 | 184 |
| Losartan Potassium | Losartan Potassium | 461 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 429 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 105 |
| Furosemide | Furosemide | 385 | 136 |
| Metformin Hcl | Metformin Hcl | 318 | 94 |
| Meloxicam | Meloxicam | 259 | 97 |
| Tizanidine Hcl | Tizanidine Hcl | 243 | 90 |
| Gabapentin | Gabapentin | 238 | 67 |
| Jardiance | Empagliflozin | 219 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 60 |
| Omeprazole | Omeprazole | 202 | 63 |
| Potassium Chloride | Potassium Chloride | 201 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 185 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 69 |
| Farxiga | Dapagliflozin Propanediol | 175 | 37 |
| Tramadol Hcl | Tramadol Hcl | 172 | 80 |
| Eliquis | Apixaban | 167 | 32 |
| Trazodone Hcl | Trazodone Hcl | 162 | 37 |
| Lisinopril | Lisinopril | 159 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 51 |
| Famotidine | Famotidine | 151 | 58 |
| Prednisone | Prednisone | 150 | 106 |
| Clonazepam | Clonazepam | 146 | 23 |
| Allopurinol | Allopurinol | 137 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 43 |
| Carvedilol | Carvedilol | 134 | 46 |
| Sertraline Hcl | Sertraline Hcl | 123 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 33 |
| Buspirone Hcl | Buspirone Hcl | 119 | 28 |
| Glimepiride | Glimepiride | 115 | 35 |
| Ozempic | Semaglutide | 108 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 42 |
| Meclizine Hcl | Meclizine Hcl | 105 | 53 |
| Mounjaro | Tirzepatide | 104 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 22 |
| Simvastatin | Simvastatin | 88 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 27 |
| Baclofen | Baclofen | 85 | 24 |
| Levofloxacin | Levofloxacin | 84 | 78 |
| Ibuprofen | Ibuprofen | 82 | 21 |
| Topiramate | Topiramate | 81 | 23 |
| Montelukast Sodium | Montelukast Sodium | 77 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 27 |
| Mirtazapine | Mirtazapine | 70 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 33 |
| Clonidine Hcl | Clonidine Hcl | 67 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 17 |
| Colchicine | Colchicine | 65 | 21 |
| Linzess | Linaclotide | 65 | 18 |
| Xarelto | Rivaroxaban | 65 | 12 |
| Azithromycin | Azithromycin | 64 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 17 |
| Ondansetron Odt | Ondansetron | 64 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 32 |
| Ezetimibe | Ezetimibe | 51 | 14 |
| Pregabalin | Pregabalin | 51 | 13 |
| Finasteride | Finasteride | 50 | 12 |
| Naproxen | Naproxen | 49 | 14 |
| Cefuroxime | Cefuroxime Axetil | 47 | 41 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 14 |
| Sucralfate | Sucralfate | 41 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 14 |
| Celecoxib | Celecoxib | 40 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 15 |
| Risperidone | Risperidone | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 13 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | 11 |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Lactulose | Lactulose | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 16 |
| Alprazolam Er | Alprazolam | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $323.64 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, EVENITY, FARXIGA, Kerendia, LOREEV XR, MOUNJARO, Ohtuvayre, Omnipod, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error